Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18675949 | 0.87 | KMT2A (0.56) | KMT2AMEN1FFAR4TDP1L3MBTL1 | |
| SCHEMBL27271383 | 0.85 | TSHR (0.57) | PKMKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL27774545 | 0.82 | KMT2A (0.56) | PKMKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL4128743 | 0.82 | PDE4B (0.51) | PKMALDH1A1FFAR4MAPTTDP1 | |
| SCHEMBL4126956 | 0.81 | PDE4D (0.50) | PKMMAPTTDP1POLBLMNA | |
| SCHEMBL18669049 | 0.79 | LMNA (0.54) | KMT2AALDH1A1MAPTTDP1GAA | |
| SCHEMBL18675951 | 0.79 | KMT2A (0.57) | PKMKMT2AMEN1ALDH1A1FFAR4 | |
| SCHEMBL6613660 | 0.79 | KMT2A (0.59) | PKMKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL22705258 | 0.78 | LMNA (0.42) | PKMKMT2AMEN1ALDH1A1FFAR4 | |
| SCHEMBL4118586 | 0.77 | HTT (0.53) | PKMKMT2AMEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190218168-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XWPharma Ltd. (KY) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218168-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | GABRB3, GABRB2, GABRB1 | PKM 1282/4885KMT2A 2813/4885MEN1 3993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.